Observational Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Aug 28, 2020; 26(32): 4866-4877
Published online Aug 28, 2020. doi: 10.3748/wjg.v26.i32.4866
Table 1 Baseline characteristics of inflammatory bowel disease patients and healthy controls
ParameterIBD group (n = 70)Control group (n = 60)P value
Men (n, %)46 (65.7)38 (63.3)0.7781
Women (n, %)24 (34.3)22 (36.7)
Age (yr)40.8 ± 14.938.7 ± 12.60.3902
Body weight (kg)77.7 ± 12.581.3 ± 13.20.1112
Body height (cm)177.7 ± 8.2180.1 ± 9.10.1322
Body mass index (kg/m2)24.6 ± 3.525.0 ± 2.80.4932
Waist circumference (cm)88.1 ± 12.688.0 ± 12.10.9972
hsCRP (mg/L)2.65 (1.0-7.8)0.75 (0.4-1.75)< 0.0013
Fecal calprotectin (μg/g)235 (56.0-658)--
Disease duration (yr)8.5 (3.5-13.0)--
UCEIS score6.0 (5.0-7.0)--
SES-CD10.3 (5.2-13.6)--
mAb therapy (n, %)48 (68.5%)--
Table 2 Multiple linear regression model of independent predictors for dephosphorylated and uncarboxylated matrix Gla protein concentration
Variableβ1SEt valueP value
Fecal calprotectin (μg/g)0.060.023.080.003
hsCRP (mg/L)0.660.471.410.162
Body mass index (kg/m2)-11.155.82-1.920.058
Age (years)1.871.131.650.102
Waist circumference (cm)4.351.722.540.013
Disease duration (yr)-3.961.81-1.840.062